News

CureVac, BioNTech and GSK

CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight against COVID-19.
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.
BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-time COVID-19 vaccine competitor.
Pfizer, BioNTech reach Covid jab settlement with GSK, CureVac
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 million
CureVac Resolves Patent Litigation with Pfizer/BioNTech
CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of the settlement,
GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation
GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation: London, UK Saturday, August 9, 2025, 10:00 Hrs [IST] GSK plc announces that, in connection with th
GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech
The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation in the US – in the wake of BioNTech's recent agreement to acquire its former rival in a $1.25 billion deal.
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. | Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.
GSK to Receive $370 Million in U.S. Patent Litigation Settlement
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.
GSK to be paid up to £370 million after patent row settles in US
CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.
InvestorsHub on MSN7h
GSK shares rise after FDA grants priority review for oral gonorrhea antibiotic
GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...
Wall Street Journal1y
GSK to Buy CureVac’s Covid-19, Flu Vaccine Rights for Up to $1.56 ...
GSK GSK 0.99% struck a deal to buy the rights to CureVac ’s CVAC -3.34% Covid-19 and flu vaccines for up to 1.45 billion euros ($1.56 billion), in a bid to regain ground lost to newcomers to the ...
STAT3d
Pharmalittle: We’re reading about Trump and drug prices, an FDA plan for U.S. manufacturing, and more
The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...